
Nuvectis Pharma, Inc.: shareholders and insiders
Price
$19.39
November 20, 2026Market cap $667M
What Ploutos Investor adds for Nuvectis Pharma
Part of Ploutos Investor, €9.99 a month
- The full history: 5 fiscal years, from 2021
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Aug 5, 2026, from their own Form 4 filings.
Bought on the market
$1.2M
2 people
Sold on the market
–
nobody
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
No sales in the period.
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $1.2M by 2 people·no sales
- 2025: no buys, no sales
- 2026: bought $1.2M by 2 people, no sales
- Aug 3, 2026Michael J. CarsonVice President, FinanceKind
- Jun 30, 2026Marlio Charles MosseriKind
- Jun 30, 2026Ron BentsurChairman & CEOKind
- Jun 11, 2026Kenneth HobermanDirectorKind
- Jun 11, 2026James F Oliviero IIIDirectorKind
- Jun 11, 2026Juan SanchezDirectorKind
- Jun 11, 2026Matthew L. KaplanDirectorKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 3, 2026 | Michael J. CarsonVice President, Finance | 30.0K | – | – | Form 4 | |
| Jun 30, 2026 | Marlio Charles Mosseri | 50.0K | $18.32 | $916.0K | Form 4 | |
| Jun 30, 2026 | Ron BentsurChairman & CEO | 12.5K | $20.00 | $250.0K | Form 4 | |
| Jun 11, 2026 | Kenneth HobermanDirector | 35.0K | – | – | Form 4 | |
| Jun 11, 2026 | James F Oliviero IIIDirector | 35.0K | – | – | Form 4 | |
| Jun 11, 2026 | Juan SanchezDirector | 35.0K | – | – | Form 4 | |
| Jun 11, 2026 | Matthew L. KaplanDirector | 35.0K | – | – | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade.
Insiders and their shares
Every buy and sale by NVCT's officers and directors from 2022 up to November 21, 2025, 4 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Soleus Private Equity Fund III, L.P.with 8 more personsShare of class5.10%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Soleus Private Equity Fund III, L.P.with 8 more persons | 5.10% | 1.65M | Aug 6, 2026 | 13G |
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter
- Citadel Advisors (Griffin)In the quarter-62%
- AQR CapitalIn the quarter+0.8%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 46.2K | $1.0M | 0.00% | |
| Citadel Advisors (Griffin) | 43.9K | -62% | $900.0K | 0.00% |
| AQR Capital | 32.1K | +0.8% | $700.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 6.98% of its shares outstanding were held short, -4.8% since the report before.
- Shares held short
- 2.40M
- 6.98%
- Since the report before2.52M on Sep 30, 2026
- -4.8%
- 13.9
- 172.4K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 97%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 290.9K
- Nov 15, 2023: Shares held short 345.5K
- Nov 30, 2023: Shares held short 348.4K
- Dec 15, 2023: Shares held short 338.8K
- Dec 29, 2023: Shares held short 362.7K
- Jan 12, 2024: Shares held short 400.6K
- Jan 31, 2024: Shares held short 503.4K
- Feb 15, 2024: Shares held short 602.2K
- Feb 29, 2024: Shares held short 723.6K
- Mar 15, 2024: Shares held short 766.1K
- Mar 28, 2024: Shares held short 808.2K
- Apr 15, 2024: Shares held short 822.6K
- Apr 30, 2024: Shares held short 944.0K
- May 15, 2024: Shares held short 1.02M
- May 31, 2024: Shares held short 1.17M
- Jun 14, 2024: Shares held short 1.15M
- Jun 28, 2024: Shares held short 1.08M
- Jul 15, 2024: Shares held short 884.2K
- Jul 31, 2024: Shares held short 841.2K
- Aug 15, 2024: Shares held short 902.5K
- Aug 30, 2024: Shares held short 924.4K
- Sep 13, 2024: Shares held short 977.0K
- Sep 30, 2024: Shares held short 989.6K
- Oct 15, 2024: Shares held short 1.05M
- Oct 31, 2024: Shares held short 1.13M
- Nov 15, 2024: Shares held short 1.39M
- Nov 29, 2024: Shares held short 1.42M
- Dec 13, 2024: Shares held short 1.44M
- Dec 31, 2024: Shares held short 1.42M
- Jan 15, 2025: Shares held short 1.48M
- Jan 31, 2025: Shares held short 1.48M
- Feb 14, 2025: Shares held short 1.56M
- Feb 28, 2025: Shares held short 1.34M
- Mar 14, 2025: Shares held short 1.49M
- Mar 31, 2025: Shares held short 1.63M
- Apr 15, 2025: Shares held short 1.63M
- Apr 30, 2025: Shares held short 1.89M
- May 15, 2025: Shares held short 2.10M
- May 30, 2025: Shares held short 2.11M
- Jun 13, 2025: Shares held short 2.12M
- Jun 30, 2025: Shares held short 2.64M
- Jul 15, 2025: Shares held short 2.64M
- Jul 31, 2025: Shares held short 1.06M
- Aug 15, 2025: Shares held short 1.02M
- Aug 29, 2025: Shares held short 982.8K
- Sep 15, 2025: Shares held short 854.6K
- Sep 30, 2025: Shares held short 987.7K
- Oct 15, 2025: Shares held short 900.8K
- Oct 31, 2025: Shares held short 1.23M
- Nov 14, 2025: Shares held short 1.33M
- Nov 28, 2025: Shares held short 1.37M
- Dec 15, 2025: Shares held short 1.43M
- Dec 31, 2025: Shares held short 1.53M
- Jan 15, 2026: Shares held short 1.62M
- Jan 30, 2026: Shares held short 1.59M
- Feb 13, 2026: Shares held short 1.65M
- Feb 27, 2026: Shares held short 1.62M
- Mar 13, 2026: Shares held short 1.62M
- Mar 31, 2026: Shares held short 1.58M
- Apr 15, 2026: Shares held short 1.54M
- Apr 30, 2026: Shares held short 1.46M
- May 15, 2026: Shares held short 1.43M
- May 29, 2026: Shares held short 1.58M
- Jun 15, 2026: Shares held short 1.57M
- Jun 30, 2026: Shares held short 1.80M
- Jul 15, 2026: Shares held short 1.51M
- Jul 31, 2026: Shares held short 1.84M
- Aug 14, 2026: Shares held short 1.84M
- Aug 31, 2026: Shares held short 2.20M
- Sep 15, 2026: Shares held short 2.36M
- Sep 30, 2026: Shares held short 2.52M
- Oct 15, 2026: Shares held short 2.40M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading64.7% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 64.7% of the shares in the reported trades were short sales, against 69.0% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 64.7%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 69.0%
- Change
- -4.3 pts
- Short sales a dayon average, of 87.6K shares
- 56.7K
- More than atof 3,666 US-listed companies, same days
- 91%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 57.2%
- Oct 15, 2026: Short sales 82.7%
- Oct 16, 2026: Short sales 74.8%
- Oct 19, 2026: Short sales 60.7%
- Oct 20, 2026: Short sales 73.6%
- Oct 21, 2026: Short sales 71.3%
- Oct 22, 2026: Short sales 83.2%
- Oct 23, 2026: Short sales 79.2%
- Oct 26, 2026: Short sales 81.5%
- Oct 27, 2026: Short sales 68.1%
- Oct 28, 2026: Short sales 59%
- Oct 29, 2026: Short sales 51%
- Oct 30, 2026: Short sales 58.1%
- Nov 2, 2026: Short sales 67.4%
- Nov 3, 2026: Short sales 71.7%
- Nov 4, 2026: Short sales 71.9%
- Nov 5, 2026: Short sales 42.9%
- Nov 6, 2026: Short sales 60.9%
- Nov 9, 2026: Short sales 65.6%
- Nov 10, 2026: Short sales 47.9%
- Nov 11, 2026: Short sales 55.4%
- Nov 12, 2026: Short sales 49.3%
- Nov 13, 2026: Short sales 69.1%
- Nov 16, 2026: Short sales 72.3%
- Nov 17, 2026: Short sales 83.2%
- Nov 18, 2026: Short sales 82.5%
- Nov 19, 2026: Short sales 84.2%
- Nov 20, 2026: Short sales 62.3%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Marlio Charles MosseriTenPercentOwnerDirectly2.61M
- Ron BentsurChairman & CEODirectly3.69M
- Enrique PoradosuChief Science & Business OffDirectly1.51M
- Shay ShemeshChief Dev. & Ops. OfficerDirectly1.49M
- Michael J. CarsonVice President, FinanceDirectly230.1K
- Kenneth HobermanDirectorDirectly168.1K
- Matthew L. KaplanDirectorDirectly159.8K
- James F Oliviero IIIDirectorDirectly122.8K
- Juan SanchezDirectorDirectly113.8K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Marlio Charles MosseriTenPercentOwner | 2.61M | 3.19M | Jun 30, 2026 | Form 4 |
| Ron BentsurChairman & CEO | 3.69M | – | Jun 30, 2026 | Form 4 |
| Enrique PoradosuChief Science & Business Off | 1.51M | – | Nov 19, 2024 | Form 4 |
| Shay ShemeshChief Dev. & Ops. Officer | 1.49M | – | May 10, 2024 | Form 4 |
| Michael J. CarsonVice President, Finance | 230.1K | – | Aug 3, 2026 | Form 4 |
| Kenneth HobermanDirector | 168.1K | – | Jun 11, 2026 | Form 4 |
| Matthew L. KaplanDirector | 159.8K | – | Jun 11, 2026 | Form 4 |
| James F Oliviero IIIDirector | 122.8K | – | Jun 11, 2026 | Form 4 |
| Juan SanchezDirector | 113.8K | – | Jun 11, 2026 | Form 4 |
A lower bound: it counts only the 9 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.07%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.02%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.01%
- IWMiShares Russell 2000 ETFWeight in the fund0.01%
- VXFVanguard Extended Market Index FundWeight in the fund0.00%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
6 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 53
- Q4 2025: Managers 48
- Q1 2026: Managers 62
- Q2 2026: Managers 83
Institutional investors by quarter
The fund managers holding NVCT, quarter by quarter, from Q1 2022 to Q2 2025, 14 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 83 managers held 10.28M shares, worth $190M. During the quarter 29 opened a position, 8 closed one, 32 added and 11 trimmed.
The largest holders, Q2 2026
- Tang Capital ManagementIn the quarter
- BlackRockIn the quarter+31%
- Soleus Capital ManagementIn the quarter
- Perceptive AdvisorsIn the quarter
- Vanguard Capital ManagementIn the quarter+32%
- Iridian Asset ManagementIn the quarter+19%
- Geode Capital ManagementIn the quarter+13%
- Sphera Funds ManagementIn the quarter
- Baldwin Wealth PartnersIn the quarter+0.9%
- Occam Crest ManagementIn the quarter-12%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Tang Capital Management | 1.55M | $29M | |
| BlackRock | 1.00M | +31% | $18M |
| Soleus Capital Management | 1.00M | $18M | |
| Perceptive Advisors | 1.00M | $18M | |
| Vanguard Capital Management | 872.5K | +32% | $16M |
| Iridian Asset Management | 777.1K | +19% | $14M |
| Geode Capital Management | 432.3K | +13% | $8.0M |
| Sphera Funds Management | 382.9K | $7.0M | |
| Baldwin Wealth Partners | 382.0K | +0.9% | $7.0M |
| Occam Crest Management | 357.1K | -12% | $7.4M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Nuvectis Pharma's filings show?
Who buys and sells is one part of Nuvectis Pharma's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have NVCT's insiders bought or sold?
From Jun 12, 2026 to Aug 5, 2026 Nuvectis Pharma's insiders bought $1.2M and sold 0 of shares on the market. – of the sales were under set 10b5-1 plans.
Which well-known managers hold NVCT?
3 of the managers we track held the shares on Sep 30, 2026. The largest position was Point72 (Cohen)'s, worth $1.0M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.